A revolution in the treatment of non-Hodgkin's lymphoma

G. L. DeNardo, R. T. O'Donnell, R. K. Oldham, S. J. DeNardo

Research output: Contribution to journalArticlepeer-review

38 Scopus citations


It was not so long ago that the words of Sammuel Johnson, 'Few enterprises of great labor or hazard would be undertaken if we had not the power of magnifying the advantages we expect from them' were applicable to development of MoAbs as vehicles for cancer treatment. Now it is apparent that MoAbs can work remarkably well under the right circumstances. We have just entered a new era of biotherapy for NHL (and other malignancies). One of the most potent ways of augmenting the cytoreductive power of MoAb treatment is to conjugate the MoAb to radionuclides, such as 131I, 67Cu and 90Y. In summary, new drugs have become available, or may soon be available, for the effective treatment of patients with currently incurable NHL. Biotherapy, seems particularly promising and likely to profoundly alter the future management of patients with NHL. Once the efficacy and toxicity of single agent treatment has been established in patients, combinations of agents will be explored.

Original languageEnglish (US)
Pages (from-to)213-223
Number of pages11
JournalCancer Biotherapy and Radiopharmaceuticals
Issue number4
StatePublished - 1998

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology


Dive into the research topics of 'A revolution in the treatment of non-Hodgkin's lymphoma'. Together they form a unique fingerprint.

Cite this